Pfizer

Pfizer Incorporated (NYSE: PFE) is a pharmaceutical company, ranking number one in sales in the world. The company is based in New York City, with its research headquarters in Groton, Connecticut. It produces Lipitor (atorvastatin, used to lower blood cholesterol); the neuropathic pain/fibromyalgia drug Lyrica (pregabalin); the oral antifungal medication Diflucan (fluconazole), the antibiotic Zithromax (azithromycin), Viagra (sildenafil) for erectile dysfunction, and the anti-inflammatory Celebrex (celecoxib) (also known as Celebra in some countries outside the USA and Canada, mainly in South America).

Big Bets Aim To Jolt Heart Drug Sales Back To Life

Patent expiries mean annual sales of 15 different categories of heart drugs are set to fall by more than a quarter by 2017, from $83 billion in 2011 to $60 billion, according to consensus analyst forecasts compiled by Thomson Reuters Pharma.

Pfizer Settles Government Bribery Complaints

Among the charges: Pfizer's China subsidiary was accused of offering a program where doctors could claim cell phones and other goodies based on how many prescriptions they doled out of the company's products.

Exercise, Meds Both Help Depressed Heart Patients

Researchers found that of 101 heart patients with signs of depression, those who exercised for 90 minutes per week and those who started taking Zoloft both improved significantly compared to participants assigned to drug-free placebo pills.

Pfizer Earnings Preview: Profit Down On Falling Sales

Pfizer Inc. (NYSE: PFE), the world's largest drug developer by revenue, is expected to report a decline in second-quarter profits on declining sales of its top-selling cholesterol drug Lipitor and generic competition for its glaucoma pill Zalatan.

Merck Second-Quarter Earnings Preview: A Glimpse

Based on analyst estimates, Merck & Co. will report earnings of $1.01 a share on sales of about $12.16 billion -- an increase of 0.1 percent from the year-earlier quarter. The company posts its second-quarter earnings on Friday, before the opening bell.

Scientists Trace Timeline Of Alzheimer's Slow, Deadly Path

A new study offers a timeline of changes in spinal fluid, brain size, the appearance of brain plaques and other factors that precede the onset of Alzheimer's in people who are genetically predestined to develop the brain-wasting disease.

Pfizer Yanks Breast, Colon Claims For Centrum Vitamins

A consumer group said Pfizer partly based its claims that Centrum products promote breast and colon health on the presence of vitamin D in the products, despite inconsistent or inconclusive evidence of vitamin D's protective role against breast and colon cancer.

India To Give Free Generic Drugs To Hundreds Of Millions

From city hospitals to tiny rural clinics, India's public doctors will soon be able to prescribe free generic drugs to all comers, vastly expanding access to medicine in a country where public spending on health was just $4.50 per person last year.

GSK Settles Healthcare Fraud Case For $3 Billion

GSK targeted the antidepressant Paxil to patients under age 18 when it was approved for adults only, and it pushed the drug Wellbutrin for uses it was not approved for, including weight loss and treatment of sexual dysfunction, according to an investigation led by the U.S. Justice Department.

Promoting Health? It's All In The Game

Gamification - turning boring, unpleasant but necessary tasks into an online game - is a new way of thinking that is gaining momentum among drugmakers and health campaigners.

Tafamidis: US Panel Split On Pfizer Rare Disease Drug

A U.S. health advisory panel on Thursday issued a split vote on data for Pfizer Inc's drug to treat a rare neurodegenerative disease. The U.S. Food and Drug Administration panel voted 13 to 4 that the drug did not show that it met the main goal in a study in treating the fatal condition.

'Breakthrough Drugs': FDA May Speed Approval Process

Experimental drugs that show a big effect early in development for treating serious or life-threatening diseases would get a faster and cheaper path to U.S. approval, under a proposal likely to become law this year. U.S. drug regulators would be able to label such treatments breakthrough therapies, and work with companies to speed up clinical trials, for example by testing the drugs for a shorter time or enrolling fewer patients.

Pages

EDITOR'S PICK